StandardAero executive Krekeler sells $10670 in shares By Investing.com

StandardAero reported record Q4 2025 results, with EPS of $0.24 and revenue of $1.6 billion, but Jefferies cut its price target to $34 from $38 and lowered Q1 EPS estimates to $0.22 versus $0.25 consensus. The article also highlights insider activity: Gregory Clemens Krekeler sold 390 shares at $27.36 for $10,670, while also exercising options and receiving RSUs/options on April 15. Overall, the news is mixed, with strong operating performance offset by a softer near-term analyst outlook.

Analysis

The clean read here is that the business is still comping off a strong operational base, but the market is starting to price in a normalization of margins before the earnings model has fully reset. That creates a classic earnings-quality gap: headline growth can remain solid while incremental profit conversion decelerates, which is where the multiple gets challenged first. The insider activity is not bearish by itself, but it does suggest the stock is entering a phase where management confidence is being expressed more through equity retention and option alignment than outright open-market buying.

Second-order beneficiaries are the adjacent MRO and aftermarket names that can pick up share if customers start rebalancing vendor concentration amid any service bottlenecks or pricing pressure. If StandardAero’s growth is partly being driven by a tight capacity environment, then any softening in lead times or OEM support dynamics can shift volume to peers faster than the market expects. That means the key competitive question is not whether demand exists, but whether the company can sustain pricing power while scaling labor and parts throughput.

The main risk is that the Street is anchoring on a high-quality franchise multiple just as estimate revisions begin to flatten. In that setup, even small guide-downs can cause disproportionate derating over the next 1-2 earnings cycles, especially if gross margin commentary stops improving. Conversely, if the company can keep revenue growth intact while proving the margin pressure is transitory, the stock can re-rate quickly because the current valuation still leaves room for a technical squeeze.

The contrarian view is that this is less a broken-story name than a crowded ‘good business, too-expensive-for-now’ setup. The market may be underestimating how quickly operating leverage reappears if utilization stabilizes and the earnings base absorbs the recent investment cycle. But until there is evidence of margin inflection, upside is likely capped by execution skepticism rather than by demand risk.

Key Decisions for Investors

• Long SARO only on post-earnings pullbacks into the low-$20s; target a rebound to the mid-$30s if margins stabilize, but stop out on any sequential gross margin compression that persists beyond one quarter.
• Sell covered calls against existing SARO exposure 1-2 expiries out; implied upside looks better monetized via premium than outright beta while the market waits for the next margin data point.
• Pair trade: long a higher-quality aftermarket/MRO peer basket versus short SARO for 1-2 quarters if estimates keep drifting lower; the relative trade should work if the market rotates toward names with cleaner margin visibility.
• Avoid initiating fresh size ahead of the next quarterly print unless there is evidence of estimate stabilization; the risk/reward is asymmetric to the downside if management guides conservatively again.
• If SARO holds above the Jefferies/PT zone after earnings, consider a momentum add only on confirmation of margin inflection; otherwise treat rallies as opportunities to de-risk.